Showing 4021-4030 of 6059 results for "".
- Arena’s Etrasimod Performs Well in Phase 2b AD Trialhttps://practicaldermatology.com/news/arenas-etrasimod-performs-well-in-phase-2b-ad-trial/2460604/Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating
- TARGET-DERM Real-World Study Expandshttps://practicaldermatology.com/news/target-derm-real-world-study-expands/2460550/Target RWE is expanding its active longitudinal dermatology registry, TARGET-DERM (
- AmorePacific Launches New Woke Skincare Brandhttps://practicaldermatology.com/news/amorepacific-launches-new-woke-skincare-brand/2460503/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In addition, Enough
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- And the Winner Is...Dr. Junko Takeshita of University of Pennsylvania Wins 2020 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/and-the-winner-isdr-junko-takeshita-of-university-of-pennsylvania-wins-2020-childhood-eczema-challenge-grant/2460481/The
- Noah Worcester Dermatological Society: No Meeting in 2020https://practicaldermatology.com/news/noah-worcester-dermatological-society-no-meeting-in-2020/2460453/
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- Cynosure Rolls Out Elite iQ Aesthetic Workstation For Laser Hair Removal, Skin Revitalizationhttps://practicaldermatology.com/news/cynosure-rolls-out-elite-iq-aesthetic-workstation-for-laser-hair-removal-skin-revitalization/2460407/
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group